Candidemia in non-neutropenic critically ill patients : analysis of prognostic factors and assessment of systemic antifungal therapy
Objective: To determine the incidence and prognosis of candidemia in non-neutropenic critically ill patients, to define mortality-related factors, and to evaluate the results of systemic antifungal therapy. Design: A prospective multicenter survey in which medical and/or surgical intensive care unit...
Gespeichert in:
| Veröffentlicht in: | Intensive care medicine 1997-01, Vol.23 (1), p.23-30 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 30 |
|---|---|
| container_issue | 1 |
| container_start_page | 23 |
| container_title | Intensive care medicine |
| container_volume | 23 |
| creator | NOLLA-SALAS, J SITGES-SERRA, A LEON-GIL, C MARTINEZ-GONZALEZ, J LEON-REGIDOR, M. A IBANEZ-LUCIA, P TORRES-RODRIGUEZ, J. M |
| description | Objective: To determine the incidence and prognosis of candidemia in non-neutropenic critically ill patients, to define mortality-related factors, and to evaluate the results of systemic antifungal therapy. Design: A prospective multicenter survey in which medical and/or surgical intensive care units (ICUs) in 28 hospitals in Spain participated. Patients: All critically ill patients with positive blood cultures for Candida species admitted to the participating ICUs over a 15-month period were included. Interventions: Candidemia was defined as the presence of at least one positive blood culture containing Candida species. The follow-up period was defined as the time elapsed from the first positive blood culture for Candida species to discharge or death during hospitalization. Antifungal therapy was considered to be "early" when it was administered within 48h of the date when the first positive blood culture was obtained and "late" when it was administered more than 48h after the first positive blood culture. Measurements and main results: Candidemia was diagnosed in 46 patients (mean age 59 years), with an incidence of 1 critically ill patient per 500 ICU admissions. The species most frequently isolated were Candida albicans (60%) and C. parapsilosis (17%). Fluconazole alone was given to 27 patients, amphotericin B alone to 10, and sequential therapy to 6. Three patients did not receive antifungal therapy. The overall mortality was 56% and the attributable mortality 21.7%. In the univariate analysis, mortality was significantly associated with a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score at the onset of candidemia (p=0.04) and with the time elapsed between the episode of candidemia and the start of antifungal therapy 48h or more later (p20 at the time of candidemia was associated with a higher mortality. Further studies with a large number of patients are needed to assess the eff |
| doi_str_mv | 10.1007/s001340050286 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1238109229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1238109229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c325t-b03e666b81d4a57c9568c6c4f2619e72fbae8468d2d22a1e3d0d010e3b495a993</originalsourceid><addsrcrecordid>eNpd0TtPHDEQAGALJRIXkjK9paRIs-D3eemiUwJISDSkXs15vcTIZy8eb7E9Pzw-gZBC5WK-mfHMEPKVs3PO2PYCGeNSMaaZsOaEbLiSouNC2g9kw6QSnTJKnJJPiI9Nbo3mG_K8gzSG0R8C0JBoyqlLfqklzz4FR10JNTiIcaUhRjpDDT5VpJcUEsQVA9I80bnkh5SxSTqBq7lgC48UED3ioSUcEa5YWxvXQjVMS3qASOtfX2BeP5OPE0T0X17fM_Ln96_73XV3e3d1s_t52zkpdO32THpjzN7yUYHeul4b64xTkzC891sx7cFbZewoRiGAezmykXHm5V71GvpenpEfL3Xbh58Wj3U4BHQ-Rkg-Lzgcd8VZL8SRfntHH_NS2sxNMS4400bbproX5UpGLH4a5hIOUNaGhuNNhv9u0vz316qAbatTgeQCviUJrXpprfwHi-2M8g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1012105658</pqid></control><display><type>article</type><title>Candidemia in non-neutropenic critically ill patients : analysis of prognostic factors and assessment of systemic antifungal therapy</title><source>SpringerLink Journals - AutoHoldings</source><creator>NOLLA-SALAS, J ; SITGES-SERRA, A ; LEON-GIL, C ; MARTINEZ-GONZALEZ, J ; LEON-REGIDOR, M. A ; IBANEZ-LUCIA, P ; TORRES-RODRIGUEZ, J. M</creator><creatorcontrib>NOLLA-SALAS, J ; SITGES-SERRA, A ; LEON-GIL, C ; MARTINEZ-GONZALEZ, J ; LEON-REGIDOR, M. A ; IBANEZ-LUCIA, P ; TORRES-RODRIGUEZ, J. M</creatorcontrib><description>Objective: To determine the incidence and prognosis of candidemia in non-neutropenic critically ill patients, to define mortality-related factors, and to evaluate the results of systemic antifungal therapy. Design: A prospective multicenter survey in which medical and/or surgical intensive care units (ICUs) in 28 hospitals in Spain participated. Patients: All critically ill patients with positive blood cultures for Candida species admitted to the participating ICUs over a 15-month period were included. Interventions: Candidemia was defined as the presence of at least one positive blood culture containing Candida species. The follow-up period was defined as the time elapsed from the first positive blood culture for Candida species to discharge or death during hospitalization. Antifungal therapy was considered to be "early" when it was administered within 48h of the date when the first positive blood culture was obtained and "late" when it was administered more than 48h after the first positive blood culture. Measurements and main results: Candidemia was diagnosed in 46 patients (mean age 59 years), with an incidence of 1 critically ill patient per 500 ICU admissions. The species most frequently isolated were Candida albicans (60%) and C. parapsilosis (17%). Fluconazole alone was given to 27 patients, amphotericin B alone to 10, and sequential therapy to 6. Three patients did not receive antifungal therapy. The overall mortality was 56% and the attributable mortality 21.7%. In the univariate analysis, mortality was significantly associated with a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score at the onset of candidemia (p=0.04) and with the time elapsed between the episode of candidemia and the start of antifungal therapy 48h or more later (p<0.02). Patients with an APACHE II score lower than 21 at the onset of candidemia had a higher probability of survival than patients who were more seriously ill (p=0.04). Patients with "early" antifungal therapy (≤48h between the onset of candidemia and the start of antifungal therapy) had a higher probability of survival compared with patients with late therapy (p=0.06). No significant differences were noted between the two groups on different antifungal therapy. Conclusions: The incidence of candidemia in ICU patients was very low. An APACHE II score >20 at the time of candidemia was associated with a higher mortality. Further studies with a large number of patients are needed to assess the effect of early antifungal therapy on the decrease in mortality associated with candidemia and to determine the appropriate dosage of fluconazole and duration of treatment.[PUBLICATION ABSTRACT]</description><identifier>ISSN: 0342-4642</identifier><identifier>EISSN: 1432-1238</identifier><identifier>DOI: 10.1007/s001340050286</identifier><identifier>CODEN: ICMED9</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Candida albicans ; Carbohydrates ; Catheters ; Emergency and intensive care: infection, septic shock ; Fungal infections ; Hospitals ; Intensive care ; Intensive care medicine ; Medical prognosis ; Medical sciences ; Mortality ; Neutropenia ; Nosocomial infections ; Patient admissions ; Physiology ; Surveillance</subject><ispartof>Intensive care medicine, 1997-01, Vol.23 (1), p.23-30</ispartof><rights>1997 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c325t-b03e666b81d4a57c9568c6c4f2619e72fbae8468d2d22a1e3d0d010e3b495a993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2549388$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>NOLLA-SALAS, J</creatorcontrib><creatorcontrib>SITGES-SERRA, A</creatorcontrib><creatorcontrib>LEON-GIL, C</creatorcontrib><creatorcontrib>MARTINEZ-GONZALEZ, J</creatorcontrib><creatorcontrib>LEON-REGIDOR, M. A</creatorcontrib><creatorcontrib>IBANEZ-LUCIA, P</creatorcontrib><creatorcontrib>TORRES-RODRIGUEZ, J. M</creatorcontrib><title>Candidemia in non-neutropenic critically ill patients : analysis of prognostic factors and assessment of systemic antifungal therapy</title><title>Intensive care medicine</title><description>Objective: To determine the incidence and prognosis of candidemia in non-neutropenic critically ill patients, to define mortality-related factors, and to evaluate the results of systemic antifungal therapy. Design: A prospective multicenter survey in which medical and/or surgical intensive care units (ICUs) in 28 hospitals in Spain participated. Patients: All critically ill patients with positive blood cultures for Candida species admitted to the participating ICUs over a 15-month period were included. Interventions: Candidemia was defined as the presence of at least one positive blood culture containing Candida species. The follow-up period was defined as the time elapsed from the first positive blood culture for Candida species to discharge or death during hospitalization. Antifungal therapy was considered to be "early" when it was administered within 48h of the date when the first positive blood culture was obtained and "late" when it was administered more than 48h after the first positive blood culture. Measurements and main results: Candidemia was diagnosed in 46 patients (mean age 59 years), with an incidence of 1 critically ill patient per 500 ICU admissions. The species most frequently isolated were Candida albicans (60%) and C. parapsilosis (17%). Fluconazole alone was given to 27 patients, amphotericin B alone to 10, and sequential therapy to 6. Three patients did not receive antifungal therapy. The overall mortality was 56% and the attributable mortality 21.7%. In the univariate analysis, mortality was significantly associated with a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score at the onset of candidemia (p=0.04) and with the time elapsed between the episode of candidemia and the start of antifungal therapy 48h or more later (p<0.02). Patients with an APACHE II score lower than 21 at the onset of candidemia had a higher probability of survival than patients who were more seriously ill (p=0.04). Patients with "early" antifungal therapy (≤48h between the onset of candidemia and the start of antifungal therapy) had a higher probability of survival compared with patients with late therapy (p=0.06). No significant differences were noted between the two groups on different antifungal therapy. Conclusions: The incidence of candidemia in ICU patients was very low. An APACHE II score >20 at the time of candidemia was associated with a higher mortality. Further studies with a large number of patients are needed to assess the effect of early antifungal therapy on the decrease in mortality associated with candidemia and to determine the appropriate dosage of fluconazole and duration of treatment.[PUBLICATION ABSTRACT]</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Candida albicans</subject><subject>Carbohydrates</subject><subject>Catheters</subject><subject>Emergency and intensive care: infection, septic shock</subject><subject>Fungal infections</subject><subject>Hospitals</subject><subject>Intensive care</subject><subject>Intensive care medicine</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Neutropenia</subject><subject>Nosocomial infections</subject><subject>Patient admissions</subject><subject>Physiology</subject><subject>Surveillance</subject><issn>0342-4642</issn><issn>1432-1238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0TtPHDEQAGALJRIXkjK9paRIs-D3eemiUwJISDSkXs15vcTIZy8eb7E9Pzw-gZBC5WK-mfHMEPKVs3PO2PYCGeNSMaaZsOaEbLiSouNC2g9kw6QSnTJKnJJPiI9Nbo3mG_K8gzSG0R8C0JBoyqlLfqklzz4FR10JNTiIcaUhRjpDDT5VpJcUEsQVA9I80bnkh5SxSTqBq7lgC48UED3ioSUcEa5YWxvXQjVMS3qASOtfX2BeP5OPE0T0X17fM_Ln96_73XV3e3d1s_t52zkpdO32THpjzN7yUYHeul4b64xTkzC891sx7cFbZewoRiGAezmykXHm5V71GvpenpEfL3Xbh58Wj3U4BHQ-Rkg-Lzgcd8VZL8SRfntHH_NS2sxNMS4400bbproX5UpGLH4a5hIOUNaGhuNNhv9u0vz316qAbatTgeQCviUJrXpprfwHi-2M8g</recordid><startdate>19970101</startdate><enddate>19970101</enddate><creator>NOLLA-SALAS, J</creator><creator>SITGES-SERRA, A</creator><creator>LEON-GIL, C</creator><creator>MARTINEZ-GONZALEZ, J</creator><creator>LEON-REGIDOR, M. A</creator><creator>IBANEZ-LUCIA, P</creator><creator>TORRES-RODRIGUEZ, J. M</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7T7</scope><scope>C1K</scope><scope>M7N</scope></search><sort><creationdate>19970101</creationdate><title>Candidemia in non-neutropenic critically ill patients : analysis of prognostic factors and assessment of systemic antifungal therapy</title><author>NOLLA-SALAS, J ; SITGES-SERRA, A ; LEON-GIL, C ; MARTINEZ-GONZALEZ, J ; LEON-REGIDOR, M. A ; IBANEZ-LUCIA, P ; TORRES-RODRIGUEZ, J. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c325t-b03e666b81d4a57c9568c6c4f2619e72fbae8468d2d22a1e3d0d010e3b495a993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Candida albicans</topic><topic>Carbohydrates</topic><topic>Catheters</topic><topic>Emergency and intensive care: infection, septic shock</topic><topic>Fungal infections</topic><topic>Hospitals</topic><topic>Intensive care</topic><topic>Intensive care medicine</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Neutropenia</topic><topic>Nosocomial infections</topic><topic>Patient admissions</topic><topic>Physiology</topic><topic>Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NOLLA-SALAS, J</creatorcontrib><creatorcontrib>SITGES-SERRA, A</creatorcontrib><creatorcontrib>LEON-GIL, C</creatorcontrib><creatorcontrib>MARTINEZ-GONZALEZ, J</creatorcontrib><creatorcontrib>LEON-REGIDOR, M. A</creatorcontrib><creatorcontrib>IBANEZ-LUCIA, P</creatorcontrib><creatorcontrib>TORRES-RODRIGUEZ, J. M</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Intensive care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NOLLA-SALAS, J</au><au>SITGES-SERRA, A</au><au>LEON-GIL, C</au><au>MARTINEZ-GONZALEZ, J</au><au>LEON-REGIDOR, M. A</au><au>IBANEZ-LUCIA, P</au><au>TORRES-RODRIGUEZ, J. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Candidemia in non-neutropenic critically ill patients : analysis of prognostic factors and assessment of systemic antifungal therapy</atitle><jtitle>Intensive care medicine</jtitle><date>1997-01-01</date><risdate>1997</risdate><volume>23</volume><issue>1</issue><spage>23</spage><epage>30</epage><pages>23-30</pages><issn>0342-4642</issn><eissn>1432-1238</eissn><coden>ICMED9</coden><abstract>Objective: To determine the incidence and prognosis of candidemia in non-neutropenic critically ill patients, to define mortality-related factors, and to evaluate the results of systemic antifungal therapy. Design: A prospective multicenter survey in which medical and/or surgical intensive care units (ICUs) in 28 hospitals in Spain participated. Patients: All critically ill patients with positive blood cultures for Candida species admitted to the participating ICUs over a 15-month period were included. Interventions: Candidemia was defined as the presence of at least one positive blood culture containing Candida species. The follow-up period was defined as the time elapsed from the first positive blood culture for Candida species to discharge or death during hospitalization. Antifungal therapy was considered to be "early" when it was administered within 48h of the date when the first positive blood culture was obtained and "late" when it was administered more than 48h after the first positive blood culture. Measurements and main results: Candidemia was diagnosed in 46 patients (mean age 59 years), with an incidence of 1 critically ill patient per 500 ICU admissions. The species most frequently isolated were Candida albicans (60%) and C. parapsilosis (17%). Fluconazole alone was given to 27 patients, amphotericin B alone to 10, and sequential therapy to 6. Three patients did not receive antifungal therapy. The overall mortality was 56% and the attributable mortality 21.7%. In the univariate analysis, mortality was significantly associated with a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score at the onset of candidemia (p=0.04) and with the time elapsed between the episode of candidemia and the start of antifungal therapy 48h or more later (p<0.02). Patients with an APACHE II score lower than 21 at the onset of candidemia had a higher probability of survival than patients who were more seriously ill (p=0.04). Patients with "early" antifungal therapy (≤48h between the onset of candidemia and the start of antifungal therapy) had a higher probability of survival compared with patients with late therapy (p=0.06). No significant differences were noted between the two groups on different antifungal therapy. Conclusions: The incidence of candidemia in ICU patients was very low. An APACHE II score >20 at the time of candidemia was associated with a higher mortality. Further studies with a large number of patients are needed to assess the effect of early antifungal therapy on the decrease in mortality associated with candidemia and to determine the appropriate dosage of fluconazole and duration of treatment.[PUBLICATION ABSTRACT]</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><doi>10.1007/s001340050286</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0342-4642 |
| ispartof | Intensive care medicine, 1997-01, Vol.23 (1), p.23-30 |
| issn | 0342-4642 1432-1238 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1238109229 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Candida albicans Carbohydrates Catheters Emergency and intensive care: infection, septic shock Fungal infections Hospitals Intensive care Intensive care medicine Medical prognosis Medical sciences Mortality Neutropenia Nosocomial infections Patient admissions Physiology Surveillance |
| title | Candidemia in non-neutropenic critically ill patients : analysis of prognostic factors and assessment of systemic antifungal therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T21%3A40%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Candidemia%20in%20non-neutropenic%20critically%20ill%20patients%20:%20analysis%20of%20prognostic%20factors%20and%20assessment%20of%20systemic%20antifungal%20therapy&rft.jtitle=Intensive%20care%20medicine&rft.au=NOLLA-SALAS,%20J&rft.date=1997-01-01&rft.volume=23&rft.issue=1&rft.spage=23&rft.epage=30&rft.pages=23-30&rft.issn=0342-4642&rft.eissn=1432-1238&rft.coden=ICMED9&rft_id=info:doi/10.1007/s001340050286&rft_dat=%3Cproquest_cross%3E1238109229%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1012105658&rft_id=info:pmid/&rfr_iscdi=true |